Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 16, 2026

Buy Nvidia Under $250 on Trump’s China Visit and Warsh’s Dovish AI Signals

View original at finance.yahoo.com
“after a $4.5 billion H20 charge in Q1 FY2026”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • OpenAI committed to 10-plus gigawatts of Nvidia systems, Anthropic to 1 gigawatt, and Meta to millions of Blackwell and Rubin GPUs

    60% confidence
  • Any thaw on H200 exports through the Trump-Xi track is pure upside to a number already guided north of $78 billion

    60% confidence
  • Reddit retail euphoria including a viral '1240% gain on NVDA' thread is a signal that tends to precede consolidation in the stock

    60% confidence
  • Hyperscaler capex commitments from OpenAI, Anthropic, and Meta are locked in and insulated from rate policy changes

    60% confidence
  • Kevin Warsh's reported willingness to keep Federal Reserve policy accommodative for AI capex protects hyperscaler spending on Nvidia systems

    60% confidence
  • Computing demand is growing exponentially and the agentic AI inflection point has arrived

    60% confidence
  • Nvidia's Q1 FY2027 guidance excludes $12.5B in potential China H200/H20 revenue that could unlock if Trump-Xi trade talks produce an export carve-out

    60% confidence
  • The accelerating push by Tencent and Alibaba into homegrown AI chips creates competitive headwinds for the China upside thesis

    60% confidence
  • NVDA at $235.74 screens attractively; analyst rates Buy under $250

    60% confidence
  • Nvidia's Q1 FY2027 revenue outlook of roughly $78.0 billion explicitly assumes zero Data Center compute revenue from China

    60% confidence

Data points we hold from this source

Federal Reserve · gdp3.75 percent_upper_bound
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Buy Nvidia Under $250 on Trump’s China Visit and Warsh’s Dovish AI Signals — Source | Via News | Finance Via News